Global SjÃ¶grenâ€™s Syndrome Market is segmented By Drug Class (Cholinergic Agonists, Off-Label Drugs), By Type (Primary Sjogrenâ€™s Syndrome, Secondary Sjogrenâ€™s Syndrome), By Distribution Channel (Hospitals, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) â€“ Share, Size, Outlook, and Opportunity Analysis, 2021-2028
SjÃ¶grenâ€™s syndrome (SS) is a chronic, autoimmune, systemic, inflammatory disorder of unknown cause.
It is characterized by dryness of the mouth, eyes, and other mucous membranes due to lymphocytic infiltration of exocrine glands and secondary gland dysfunction.
There is currently no cure for SjÃ¶grenâ€™s syndrome, but there are treatments that can help relieve the symptoms.
Download Free Sample: https://www.datamintelligence.com/download-sample/sjogrens-syndrome-market
Global SjÃ¶grenâ€™s syndrome market will reach USD 2 billion by 2024, driven primarily by the launch of Bristol-Myers Squibbâ€™s Orencia from 2021.
Other factors driving the market include the growing patient population of diseases that can cause SS such as lupus and rheumatoid arthritis.
Increasing awareness and hence the demand for advanced treatment.
However, the lack of a cure for SjÃ¶grenâ€™s syndrome will impact market growth.
Many of the currently available treatments for SS either only relieve the symptoms or are considered ineffective in many patients.
Global SjÃ¶grenâ€™s syndrome market report segments the market by type, by drug class, by distribution channel, and by region.
Based on the type, the market is segmented into primary Sjogrenâ€™s syndrome and secondary.
Secondary Sjogrenâ€™s syndrome segment dominates the market.
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
North America is the largest market for SjÃ¶grenâ€™s syndrome owing to the rising prevalence of autoimmune diseases and advanced autoimmune diagnostic testing and screening.
Market Scope of the Report:
The report also profiles companies in the SjÃ¶grenâ€™s syndrome market â€“ Novartis AG, Allergan Inc., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Argentis Pharmaceuticals, LLC., Auven Therapeutics, Bridge Pharma Inc. and Cellzome GmbH.
By Drug Class
â€¢ Cholinergic Agonists
â€¢ Off-Label Drugs
â€¢ Primary Sjogrenâ€™s Syndrome
â€¢ Secondary Sjogrenâ€™s Syndrome
By Distribution Channel
â€¢ Retail Pharmacy
â€¢ Online Pharmacy
â€¢ Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
â€¢ Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
â€¢ North America (The USA, Canada, Mexico)
â€¢ South America (Brazil, Argentina, Rest of South America)
â€¢ Rest of the World
Why purchase the report?
Visualize the composition of SjÃ¶grenâ€™s syndrome market across each indication, regarding type and treatment options, highlighting the vital commercial assets and players.
Identify commercial opportunities in SjÃ¶grenâ€™s syndrome market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the market â€“ level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for crucial SjÃ¶grenâ€™s syndrome treatments of all major market players.
â€¢ Equipment Suppliers/ Buyers
â€¢ Service Providers/ Buyers
â€¢ Industry Investors/Investment Bankers
â€¢ Education & Research Institutes
â€¢ Research Professionals
â€¢ Emerging Companies
â€¢ Polycystic Ovary Syndrome Market
â€¢ Marfan Syndrome Treatment Market
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sales Manager at DataM Intelligence
Tel: +1 877 441 4866